Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023
For the full year, total revenue is expected to be over $71 million as compared to previously stated guidance of $70.0 million to $72.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.78 USD | +1.71% |
|
-2.20% | -38.62% |
May. 15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
May. 14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
1st Jan change | Capi. | |
---|---|---|
-38.62% | 53.4M | |
+0.91% | 204B | |
+3.74% | 178B | |
+28.89% | 154B | |
+31.66% | 112B | |
+1.14% | 64.32B | |
+19.45% | 54.88B | |
-2.27% | 47.24B | |
-9.28% | 36.8B | |
-0.10% | 35.26B |